Eisai Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 13 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/05/15 | ¥14.57 | ¥-11.53 | -179.1% |
| 2026/02/09 | ¥60.51 | ¥60.94 | +0.7% |
| 2025/11/04 | ¥49.45 | ¥36.02 | -27.2% |
| 2025/08/04 | ¥39.33 | ¥51.35 | +30.6% |
Shareholder Composition
Updated 2026/08/01Top Mutual Funds / ETFs
Updated 2026/08/01Major Holders
Updated 2026/08/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
7.3M | -13.80% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
3.9M | -0.49% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
2.6M | +2.59% | |
|
HARTFORD MUTUAL FUNDS INC/CT-The Hartford International Value Fund
|
1.9M | +10.60% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.9M | 0.00% | |
|
iShares, Inc.-iShares MSCI Japan ETF
|
1.1M | +4.56% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
2.4K | +2.89% |
Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥80 | -50.0% |
| 2025 | ¥160 | 0.0% |
| 2024 | ¥160 | 0.0% |
| 2023 | ¥160 | 0.0% |
| 2022 | ¥160 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥756,226M | ¥744,402M | ¥741,751M | ¥789,400M |
| Gross Profit | ¥581,395M | ¥566,566M | ¥586,417M | ¥620,593M |
| Operating Income | ¥53,750M | ¥40,040M | ¥53,407M | ¥54,377M |
| Pretax Income | ¥56,150M | ¥47,278M | ¥64,211M | ¥64,584M |
| Net Income | ¥47,954M | ¥55,432M | ¥42,407M | ¥46,433M |
| EPS | ¥167.25 | ¥193.31 | ¥147.86 | ¥163.76 |
| Operating Margin | 7.11% | 5.38% | 7.20% | 6.89% |
| Balance Sheet | ||||
| Total Assets | ¥1,239,315M | ¥1,263,350M | ¥1,393,799M | ¥1,386,547M |
| Total Equity | ¥748,821M | ¥799,959M | ¥875,614M | ¥841,417M |
| Total Liabilities | ¥490,494M | ¥463,391M | ¥518,185M | ¥545,130M |
| Cash | ¥309,633M | ¥267,350M | ¥304,678M | ¥265,561M |
| Interest-bearing Debt | ¥94,893M | ¥126,105M | ¥159,405M | ¥187,523M |
| Equity Ratio | 60.42% | 63.32% | 62.82% | 60.68% |
| D/E Ratio | 0.13 | 0.16 | 0.18 | 0.22 |
| Cash Flow | ||||
| Operating CF | ¥117,590M | -¥1,772M | ¥55,993M | ¥30,117M |
| Investing CF | -¥28,848M | -¥22,723M | -¥25,321M | -¥10,097M |
| Financing CF | -¥48,967M | -¥24,522M | -¥22,720M | -¥57,809M |
| Free CF | ¥77,123M | -¥36,331M | ¥31,170M | ¥7,148M |
| Efficiency | ||||
| ROE | 6.40% | 6.93% | 4.84% | 5.52% |
| ROA | 3.87% | 4.39% | 3.04% | 3.35% |
Latest IR Information
-
First Quarter Financial Results for Fiscal Year Ending March 2027 IFRS (Consolidated) [Supplement: Financial Results Summary Document]
Net sales were 234,330 million yen, up 15.6% YoY; operating income was 24,728 million yen, up 19.2% YoY. Quarterly net income was 19,151 million yen. Segment results were solid in Japan, the Americas, China, EMEA, East Asia & Global South....
Read more -
FY2026 Q1 Consolidated IFRS Financial Results
Revenue for FY2026 Q1 was 234.3 billion yen, with full-year guidance of 883.5 billion yen and progress of 26.5%. Growth driven by the pharmaceutical business, with contributions from key products such as Lenivima, Lequenbi, and Deebigo. Considering exchange rate impact...
Read more -
Financial Summary for the First Quarter of Fiscal Year 2026
Key financial indicators such as net sales, operating income, and net income are disclosed, with explanations of segment-wise sales and growth drivers (3L product lineup, drivers of pharmaceutical business revenue). Includes outlook, progress, and IFRS consolidated results among related information.
Read more -
【Eisai】Anti-Amyloid β Antibody Sales of ¥29.3 Billion｜Q1 2026
Eisai’s anti-Amyloid β antibody "Leqemba®" generated sales revenue of ¥29.3 billion in Q1 2026, an increase from ¥23.1 billion in the same period last year. Key sales performances are shown in the US, Japan, and China. The product is being...
Read more -
Approval for Anti-Alzheimer's Drug Acquisition | July 2026
Eisai has obtained approval from the U.S. FDA for the early Alzheimer's disease treatment with the anti-Aβ antibody "Lecenvi®" in the form of the subcutaneous injection "LEQEMBI IQLIK®" and plans to launch it in the United States in late August...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥4,482
Rating Score: 2.50 (Based on 13 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
